Courtesy: National Eye Institute, National Institutes of Health (NEI/NIH) A new study offers an explanation for how years of chronic sunlight exposure can increase the risk of cataract, a clouding of the eye lens that typically occurs with aging. The study firms up a link between the sun’s damaging rays and a process called oxidative [Read More]
News
Squalamine Eye Drops Under Study for Wet AMD
(Updated 4/17/16) On June 24, 2014, Ohr Pharmaceutical, Inc. announced positive top-line interim results for its Phase 2 clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (wet AMD). The data demonstrated a positive benefit in multiple visual function including a gain in visual acuity of +10.4 letters with Squalamine eye [Read More]
StemCells, Inc. Closes Enrollment in Dry AMD Trial
Phase II Clinical Trial to Begin This Year StemCells, Inc. yesterday announced that, based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study. Exceeding the company’s expectations, interim results showed [Read More]
Omega-3 Inhibits Retinal Blood Vessel Growth
Researchers from Massachusetts Eye and Ear/Schepens Eye Research Institute, Harvard Medical School and other institutions have demonstrated for the first time that the omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), DHA and EPA, can inhibit choroidal neovascularization (CNV). Their findings will be published in PNAS Online Early Edition the week of June 16-20, 2014. “These are [Read More]
Stem Cell Trial for Myopic Macular Degeneration
Advanced Cell Technology (ACT) announced in a shareholders’ conference call on June 9, 2014, that it has initiated its myopic macular degeneration (MMD) trial at Jules Stein Eye Institute at UCLA. The open-label study will enroll 12 patients, with cohorts of 3 patients each in an ascending dosage format. As with it’s current trials for [Read More]